These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 24656175)

  • 1. Immune response to live-attenuated Japanese encephalitis vaccine (JE-CV) neutralizes Japanese encephalitis virus isolates from south-east Asia and India.
    Bonaparte M; Dweik B; Feroldi E; Meric C; Bouckenooghe A; Hildreth S; Hu B; Yoksan S; Boaz M
    BMC Infect Dis; 2014 Mar; 14():156. PubMed ID: 24656175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistence of Wild-Type Japanese Encephalitis Virus Strains Cross-Neutralization 5 Years After JE-CV Immunization.
    Feroldi E; Boaz M; Yoksan S; Chokephaibulkit K; Thisyakorn U; Pancharoen C; Monfredo C; Bouckenooghe A
    J Infect Dis; 2017 Jan; 215(2):221-227. PubMed ID: 27815383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity of a Japanese encephalitis chimeric virus vaccine as a booster dose after primary vaccination with SA14-14-2 vaccine in Thai children.
    Janewongwirot P; Puthanakit T; Anugulruengkitt S; Jantarabenjakul W; Phasomsap C; Chumket S; Yoksan S; Pancharoen C
    Vaccine; 2016 Oct; 34(44):5279-5283. PubMed ID: 27628323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sero-Molecular Epidemiology of Japanese Encephalitis in Zhejiang, an Eastern Province of China.
    Pan JR; Yan JY; Zhou JY; Tang XW; He HQ; Xie RH; Mao HY; Zhang YJ; Xie SY
    PLoS Negl Trop Dis; 2016 Aug; 10(8):e0004936. PubMed ID: 27560360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low Protective Efficacy of the Current Japanese Encephalitis Vaccine against the Emerging Genotype 5 Japanese Encephalitis Virus.
    Cao L; Fu S; Gao X; Li M; Cui S; Li X; Cao Y; Lei W; Lu Z; He Y; Wang H; Yan J; Gao GF; Liang G
    PLoS Negl Trop Dis; 2016 May; 10(5):e0004686. PubMed ID: 27139722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of protection against Japanese encephalitis virus and JE vaccine (IXIARO(®)) induced neutralizing antibody titers.
    Van Gessel Y; Klade CS; Putnak R; Formica A; Krasaesub S; Spruth M; Cena B; Tungtaeng A; Gettayacamin M; Dewasthaly S
    Vaccine; 2011 Aug; 29(35):5925-31. PubMed ID: 21723353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Partially neutralizing potency against emerging genotype I virus among children received formalin-inactivated Japanese encephalitis virus vaccine.
    Fan YC; Chen JM; Chiu HC; Chen YY; Lin JW; Shih CC; Chen CM; Chang CC; Chang GJ; Chiou SS
    PLoS Negl Trop Dis; 2012; 6(9):e1834. PubMed ID: 23029592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cross-protection elicited by primary and booster vaccinations against Japanese encephalitis: a two-year follow-up study.
    Erra EO; Askling HH; Yoksan S; Rombo L; Riutta J; Vene S; Lindquist L; Vapalahti O; Kantele A
    Vaccine; 2013 Dec; 32(1):119-23. PubMed ID: 24176496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized study of the immunogenicity and safety of Japanese encephalitis chimeric virus vaccine (JE-CV) in comparison with SA14-14-2 vaccine in children in the Republic of Korea.
    Kim DS; Houillon G; Jang GC; Cha SH; Choi SH; Lee J; Kim HM; Kim JH; Kang JH; Kim JH; Kim KH; Kim HS; Bang J; Naimi Z; Bosch-Castells V; Boaz M; Bouckenooghe A
    Hum Vaccin Immunother; 2014; 10(9):2656-63. PubMed ID: 25483480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low population Japanese encephalitis virus (JEV) seroprevalence in Udayapur district, Nepal, three years after a JE vaccination programme: A case for further catch up campaigns?
    Turtle L; Brindle HE; Schluter WW; Faragher B; Rayamajhi A; Bohara R; Gurung S; Shakya G; Yoksan S; Dixit S; Rajbhandari R; Paudel B; Adhikari S; Solomon T; Griffiths MJ
    PLoS Negl Trop Dis; 2019 Apr; 13(4):e0007269. PubMed ID: 30986252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The immunogenicity of tetravalent dengue DNA vaccine in mice pre-exposed to Japanese encephalitis or Dengue virus antigens.
    Prompetchara E; Ketloy C; Keelapang P; Sittisombut N; Ruxrungtham K
    Asian Pac J Allergy Immunol; 2015 Sep; 33(3):182-8. PubMed ID: 26342114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity of live attenuated Japanese encephalitis SA 14-14-2 vaccine among Sri Lankan children with previous receipt of inactivated JE vaccine.
    Wijesinghe PR; Abeysinghe MRN; Yoksan S; Yao Y; Zhou B; Zhang L; Fleming JA; Marfin AA; Victor JC
    Vaccine; 2016 Nov; 34(48):5923-5928. PubMed ID: 27773472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Five-Year Antibody Persistence Following a Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) Booster in JE-CV-Primed Children in the Philippines.
    Capeding MR; Alberto ER; Bouckenooghe A; Laot TM; Chansinghakul D; Monfredo C; Machabert T; Feroldi E
    J Infect Dis; 2018 Jan; 217(4):567-571. PubMed ID: 29325161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protection against Japanese encephalitis virus strains representing four genotypes by passive transfer of sera raised against ChimeriVax-JE experimental vaccine.
    Beasley DW; Li L; Suderman MT; Guirakhoo F; Trent DW; Monath TP; Shope RE; Barrett AD
    Vaccine; 2004 Sep; 22(27-28):3722-6. PubMed ID: 15315852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of cross-reactivity between flaviviruses with sera of patients with Japanese encephalitis showed the importance of neutralization tests for the diagnosis of Japanese encephalitis.
    Maeki T; Tajima S; Ikeda M; Kato F; Taniguchi S; Nakayama E; Takasaki T; Lim CK; Saijo M
    J Infect Chemother; 2019 Oct; 25(10):786-790. PubMed ID: 31105002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Study on the protective efficacy of SA14-14-2 attenuated Japanese encephalitis against different JE virus isolates circulating in China.
    Liu X; Yu Y; Li M; Liang G; Wang H; Jia L; Dong G
    Vaccine; 2011 Mar; 29(11):2127-30. PubMed ID: 21237278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term Immunogenicity of a Single Dose of Japanese Encephalitis Chimeric Virus Vaccine in Toddlers and Booster Response 5 Years After Primary Immunization.
    Kosalaraksa P; Watanaveeradej V; Pancharoen C; Capeding MR; Feroldi E; Bouckenooghe A
    Pediatr Infect Dis J; 2017 Apr; 36(4):e108-e113. PubMed ID: 28030526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Neutralizing Antibody Titers against Japanese Encephalitis Virus Genotype V Strain with Those against Genotype I and III Strains in the Sera of Japanese Encephalitis Patients in Japan in 2016.
    Maeki T; Tajima S; Kyaw AK; Matsumoto F; Miura K; Yamashita A; Yoshikawa A; Negishi K; Noguchi Y; Tadokoro K; Abe K; Taruya J; Koh J; Ito H; Ikegaya A; Abe F; Wada M; Nishigata T; Ikeda M; Kato F; Taniguchi S; Nakayama E; Takasaki T; Morita K; Lim CK; Saijo M
    Jpn J Infect Dis; 2018 Sep; 71(5):360-364. PubMed ID: 29962489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Memory immune response and safety of a booster dose of Japanese encephalitis chimeric virus vaccine (JE-CV) in JE-CV-primed children.
    Feroldi E; Capeding MR; Boaz M; Gailhardou S; Meric C; Bouckenooghe A
    Hum Vaccin Immunother; 2013 Apr; 9(4):889-97. PubMed ID: 23442823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Envelope protein gene based molecular characterization of Japanese encephalitis virus clinical isolates from West Bengal, India: a comparative approach with respect to SA14-14-2 live attenuated vaccine strain.
    Sarkar A; Banik A; Pathak BK; Mukhopadhyay SK; Chatterjee S
    BMC Infect Dis; 2013 Aug; 13():368. PubMed ID: 23927571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.